• Search History (Register)
  • MeSH Browser

Welcome to the international HTA database


Showing [21592 Records] Selected Records [0 Hits] [Clear]
Year Source Title
2011     Secretaria de Ciencia, Tecnologia e Insumos Estrategicos, Departamento de Ciencia e Tecnologia (DECIT-CGATS ) [Evaluation of multiple technologies for chronic wounds and burns]
2021     Agència de Qualitat i Avaluació Sanitàries de Catalunya (AQuAS) [Evaluation of mHealth-based technology for mobile applications]
2009     German Agency for Health Technology Assessment at the German Institute for Medical Documentation and Information (DAHTA DIMDI) [Evaluation of medical and health economic effectiveness of non-pharmacological secondary prevention of coronary heart disease]
2008     German Agency for Health Technology Assessment at the German Institute for Medical Documentation and Information (DAHTA DIMDI) [Evaluation of medical and health economic effectiveness of bariatric surgery (obesity surgery) versus conservative strategies in adult patients with morbid obesity]
2014     Institut universitaire de cardiologie et de pneumologie de Québec – Université Laval (IUCPQ-ULaval) [Evaluation of measures related to the prevention of multiple falls in hospitalized elderly people]
2009     The Netherlands Organisation for Health Research and Development (ZonMw) [Evaluation of l-caldesmon as biomarker for brain tumor monitoring]
2023     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Evaluation of invitation letters and information for insured persons on colorectal cancer screening]
2009     Finnish Office for Health Care Technology Assessment (Finohta) [Evaluation of implementation of foetal screening]
2016     Haute Autorite de sante (HAS) [Evaluation of gene amplification for diagnosis Herpesviridae infections (cytomegalovirus, herpes simplex virus and varicella-zoster) in people living with HIV]
2009     Agence d'évaluation des technologies et des modes d'intervention en santé (AETMIS) [Evaluation of ethylene oxide sterilant alternatives: plasma and ozone]
2014     Unidad de Evaluacion de Tecnologias Sanitarias (UETS) [Evaluation of efficiency of organizational models for stroke management (stroke units)]
2013     Unidad de Evaluacion de Tecnologias Sanitarias (UETS) [Evaluation of efficacy and safety of PET-CT (update)]
2023     Agència de Qualitat i Avaluació Sanitàries de Catalunya (AQuAS) [Evaluation of early intervention programs in psychosis for adolescents and young adults]
2010     Ludwig Boltzmann Institut fuer Health Technology Assessment (LBI-HTA) [Evaluation of diagnostic technologies - background, challenges, methods]
2016     Basque Office for Health Technology Assessment (OSTEBA) [Evaluation of care times for the main cancer sites: colon/rectum, lung, breast and prostate]
2014     Basque Office for Health Technology Assessment (OSTEBA) [Evaluation of care quality in the national health service towards severe childhood mental disorders. A study in infant/juvenile mental health services]
2013     Basque Office for Health Technology Assessment (OSTEBA) [Evaluation of bubble humidification systems in low-flow oxygen therapy. Systematic review and cost analysis]
2018     Institut universitaire de cardiologie et de pneumologie de Québec – Université Laval (IUCPQ-ULaval) [Evaluation of ambulatory electrocardiography technologies for the diagnosis of cardiac arrhythmia]
2013     Basque Office for Health Technology Assessment (OSTEBA) [Evaluation and impact of a primary care-based telemonitoring intervention in home care patients with heart failure or chronic lung disease. Randomised controlled trial. The TELBIL study]
2013     Basque Office for Health Technology Assessment (OSTEBA) [Evaluating the implementation of diagnostic telemedicine in the field of dermatology]
2023     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Etranacogene dezaparvovec (haemophilia B) - Assessment according to §35a (para. 1, sentence 11) Social Code Book V]
2014     Institut national d'excellence en sante et en services sociaux (INESSS) [ETIAMEST I & II: Highlights]
2017     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Etelcalcetide (secondary hyperparathyroidism) - Benefit assessment according to §35a Social Code Book V]
2017     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Etelcalcetide (secondary hyperparathyroidism) - Addendum]
2013     Institute for Clinical Effectiveness and Health Policy (IECS) [Etanercept, adalimumab, infliximab and golimumab for the treatment of juvenile idiopathic arthritis]
2006     Unit of Health Economics and Technology Assessment in Health Care (HunHTA) [Etanercept in patients with juvenile idiopathic arthritis: systematic review and economic evaluation]
2010     Catalan Agency for Health Information, Assessment and Quality (CAHIAQ -formerly CAHTA) [Estimation of incidence of urinary incontinence associated with pregnancy and childbirth]
2003     Center for Medical Technology Assessment (CMT) [Estimating health care need]
2013     Andalusian Health Technology Assessment Area (AETSA) [Esteem® totally implantable hearing device for treatment of sensorineural hearing loss. Systematic review]
2008     Basque Office for Health Technology Assessment (OSTEBA) [Establishing standards, records and analytical procedures for the treatment of ulcerative colitis]
2023     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Esketamine (treatment-resistant major depressive disorder) – Benefit assessment according to §35a Social Code Book V]
2023     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Esketamine (treatment-resistant major depressive disorder) – Addendum to Commission A23-18]
2021     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Esketamine (depression) - Benefit assessment according to §35a Social Code Book V]
2021     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Esketamine (depression, acute treatment) - Benefit assessment according to §35a Social Code Book V]
2021     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Esketamine (depression, acute treatment) - Addendum to Commission A21-25]
2018     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Ertugliflozin/sitagliptin (type 2 diabetes mellitus) - Benefit assessment according to §35a Social Code Book V]
2022     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Ertugliflozin (type 2 diabetes mellitus) - Benefit assessment according to §35a Social Code Book V]
2022     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Ertugliflozin (type 2 diabetes mellitus) - Addendum to Commission A21-158]
2016     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Eribulin (new therapeutic indication) - Benefit assessment according to §35a Social Code Book V]
2014     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Eribulin (new therapeutic indication) - Benefit assessment according to § 35a Social Code Book V (dossier assessment)]
2016     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Eribulin (liposarcoma) - Addendum A16-31
2015     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Eribulin (Addendum to Commission A14-25)]
2012     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Eribulin - Benefit assessment according to § 35a Social Code Book V (dossier assessment)]
2019     Institute for Clinical Effectiveness and Health Policy (IECS) [Erenumab in migraine prevention]
2019     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Erenumab (prophylaxis of migraine) - Benefit assessment according to §35a Social Code Book V]
2021     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Erenumab (migraine) - Benefit assessment according to §35a Social Code Book V (new scientific findings)]
2009     Committee for New Health Technology Assessment (CNHTA) [ERCC1 RNA RT-PCR quantification]
2022     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Eravacycline (complicated intra-abdominal infections) - Assessment according to §35a (para. 1c) Social Code Book V]
2021     Institute for Clinical Effectiveness and Health Policy (IECS) [Equine immunoglobulin F(ab’)2 fragments (hyperimmune equine serum) for COVID-19]
2022     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Eptinezumab (migraine) - Benefit assessment according to §35a Social Code Book V]
2009     Committee for New Health Technology Assessment (CNHTA) [Epstein-Barr virus VCA IgA]
2009     Committee for New Health Technology Assessment (CNHTA) [Epstein-Barr virus EA IgA]
2019     Institute for Clinical Effectiveness and Health Policy (IECS) [Eposterior tibial nerve stimulation in overactive bladder and bowel incontinence]
2004     Danish Centre for Evaluation and Health Technology Assessment (DACEHTA) [Epoetin (EPO) for anaemic cancer patients]
2007     The Netherlands Organisation for Health Research and Development (ZonMw) [Epileptic source localization with EEG-correlated functional MRI]
2018     Andalusian Health Technology Assessment Area (AETSA) [Epigenetic profile for the identification of primary cancer of unknown origin]
2018     Canary Health Service [Epidermal growth factor for the treatment of diabetic foot ulcers]
2017     Institute for Clinical Effectiveness and Health Policy (IECS) [Epidermal growth factor (Heberprot-P®) in chronic ulcers]
2021     Austrian Institute for Health Technology Assessment (AIHTA) [Epidemiology of long COVID: a preliminary report. German short version of the original KCE report]
2003     Unit of Health Economics and Technology Assessment in Health Care (HunHTA) [Epidemiology and costs of osteoarthritis and rheumatoid arthritis in Hungary]
2008     Basque Office for Health Technology Assessment (OSTEBA) [Epidemiological analysis of information collected by hospital cancer registries in the Basque Autonomous Community. Identification of possible improvements with regard to the feedback and dissemination of results]
2024     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Epcoritamab (relapsed or refractory diffuse large B-cell lymphoma) – Assessment according to §35a (para. 1, sentence 11) Social Code Book V]
2011     Catalan Agency for Health Information, Assessment and Quality (CAHIAQ -formerly CAHTA) [Enzyme replacement therapy in mucopolysaccharidoses I, II and VI; 2011]
2018     Agència de Qualitat i Avaluació Sanitàries de Catalunya (AQuAS) [Enzyme replacement therapy in lysosomal storage diseases: systematic review and budgetary impact. Update]
2011     Catalan Agency for Health Information, Assessment and Quality (CAHIAQ -formerly CAHTA) [Enzymatic replacement treatment for type I gaucher's disease patients]
2021     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Enzalutamide (prostate cancer) - Benefit assessment according to §35a Social Code Book V]
2019     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Enzalutamide (prostate cancer) - Benefit assessment according to §35a Social Code Book V]
2020     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Enzalutamide (prostate cancer) - Benefit assessment according to §35a Social Code Book V (expiry of the decision)]
2021     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Enzalutamide (prostate cancer) - Addendum to Commission A21-77]
2019     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Enzalutamide (prostate cancer) - Addendum to Commission A18-80]
2015     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Enzalutamide (new therapeutic indication) - Benefit assessment according to §35a Social Code Book V (dossier assessment)]
2013     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Enzalutamide - Benefit assessment according to § 35a Social Code Book V (dossier assessment)]
2020     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Entrectinib (solid tumours expressing a neurotrophic tyrosine receptor kinase (NTRK) gene fusion) - Benefit assessment according to §35a Social Code Book V]
2021     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Entrectinib (solid tumours expressing a neurotrophic tyrosine receptor kinase (NTRK) gene fusion) - Addendum to Commission A20-74]
2020     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Entrectinib (NSCLC) - Benefit assessment according to §35a Social Code Book V]
2021     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Entrectinib (NSCLC) - Addendum to Commission A20-75]
2011     Committee for New Health Technology Assessment (CNHTA) [Enterovirus real-time rt-pcr]
2013     Basque Office for Health Technology Assessment (OSTEBA) [Enhancing the quality of information on colorectal and prostate cancer in the population cancer register of the Basque Country (RCE) and bibliographical review]
2022     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Enfortumab vedotin (urothelial carcinoma) - Addendum to Commission A22-61]
2022     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Enfortumab vedotin (urothelial cancer) - Benefit assessment according to §35a Social Code Book V]
2022     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Enfortumab vedotin (urothelial cancer) - 2nd addendum to commission A22-61]
2023     Austrian Institute for Health Technology Assessment (AIHTA) [Endovenous laser therapy for varicose veins in the lower extremities]
2020     Scientific Advice Unit, avalia-t; The Galician Health Knowledge Agency (ACIS) [Endovascular treatment of varicose veins by radiofrequency ablation or cyanoacrylate closure]
2009     Andalusian Health Technology Assessment Area (AETSA) [Endovascular treatment of cerebrovascular disease]
2009     Andalusian Health Technology Assessment Area (AETSA) [Endovascular treatment of cerebrovascular disease]
2009     Andalusian Health Technology Assessment Area (AETSA) [Endovascular treatment of cerebrovascular disease]
2009     Andalusian Health Technology Assessment Area (AETSA) [Endovascular treatment for thoracic aorta lesions]
2009     Andalusian Health Technology Assessment Area (AETSA) [Endovascular treatment for thoracic aorta lesions]
2016     Haute Autorite de sante (HAS) [Endovascular thrombectomy of intracranial arteries]
2019     Institute for Clinical Effectiveness and Health Policy (IECS) [Endovascular thrombectomy in acute ischemic stroke]
2018     Institute for Clinical Effectiveness and Health Policy (IECS) [Endovascular thrombectomy in acute ischemic stroke]
2016     Ludwig Boltzmann Institut fuer Health Technology Assessment (LBI-HTA) [Endovascular therapy using mechanical thrombectomy devices for acute ischaemic stroke. National Report: German Summary of the correspondent EUnetHTA Report]
2015     Institute for Clinical Effectiveness and Health Policy (IECS) [Endovascular repair of thoracic and thoraco-abdominal aortic aneurysm]
2013     Ludwig Boltzmann Institut fuer Health Technology Assessment (LBI-HTA) [Endovascular repair of aortic aneurysms]
2015     Institute for Clinical Effectiveness and Health Policy (IECS) [Endovascular repair in abdominal aortic aneurysm]
2012     Institute for Clinical Effectiveness and Health Policy (IECS) [Endovascular laser treatment versus saphenectomy for the management of varicose veins in lower limbs]
2015     Institute for Clinical Effectiveness and Health Policy (IECS) [Endovascular laser treatment of varicose veins of the lower limbs]
2021     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Endovascular implantation of a stent graft with a valve component for tricuspid regurgitation - Assessment according to §137h Social Code Book V]
2021     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Endovascular implantation of a stent graft with a valve component for tricuspid regurgitation - Addendum to commission H20-08]
2012     The Regional Health Technology Assessment Centre (HTA-centrum) [Endovascular contra open surgical treatment of symptom generating atherosclerotic lesions of the external iliac artery]